SOLIGENIX, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent
SOLIGENIX, INC. (SNGX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent of 0.10% for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign · last filed 2025-03-21
- SOLIGENIX, INC. effective income tax rate reconciliation, tax credit, foreign, percent for fiscal 2023 was 0.10%, a 50.00% decline from fiscal 2022.
- SOLIGENIX, INC. effective income tax rate reconciliation, tax credit, foreign, percent for fiscal 2022 was 0.20%, a 100.00% increase from fiscal 2021.
- SOLIGENIX, INC. effective income tax rate reconciliation, tax credit, foreign, percent for fiscal 2021 was 0.10%, a 0.00% change from fiscal 2020.
- SOLIGENIX, INC. effective income tax rate reconciliation, tax credit, foreign, percent for fiscal 2020 was 0.10%, a 66.67% decline from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent 12 month |
|---|---|
| 2023-12-31 | 0.10% 10-K · filed 2025-03-21 |
| 2022-12-31 | 0.20% 10-K · filed 2024-03-15 |
| 2021-12-31 | 0.10% 10-K · filed 2023-03-31 |
| 2020-12-31 | 0.10% 10-K · filed 2022-03-29 |
| 2019-12-31 | 0.30% 10-K · filed 2021-03-30 |
| 2018-12-31 | 0.20% 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |